Galmed rises on positive results from NASH drug study
04/01/2023 16:23
** Shares of Israel-based drug developer Galmed
Pharmaceuticals Ltd GLMD.O up 19.5% at 85 cents
** Co says its experimental drug to treat nonalcoholic
steatohepatitis (NASH) shows statistically significant
improvement in liver scarring in a late-stage study urn:newsml:reuters.com:*:nPn3vSVc0a
** NASH is a serious progressive liver disease caused by
excessive fat accumulation in the liver
** The drug candidate, aramchol, showed fibrosis improvement
in 39% of patients enrolled in the study, according to
Nonalcoholic Steatohepatitis Clinical Research Network - GLMD
** Co plans to submit data to the U.S. health regulator to
begin discussions to include more sensitive reading
methodologies for changes in tissue structures as goals in NASH
trials
** GLMD says it is looking for partnering opportunities to
continue aramchol's development
** GLMD shares fell 72.5% in 2022
(Reporting by Mariam E Sunny)
((Mariam.ESunny@thomsonreuters.com;))